Zacks Research Has Weak Estimate for Qiagen FY2025 Earnings

Qiagen N.V. (NYSE:QGEN) – Stock analysts at Zacks Research cut their FY2025 EPS estimates for shares of Qiagen in a report released on Thursday, January 22nd. Zacks Research analyst Team now anticipates that the company will post earnings of $2.38 per share for the year, down from their previous estimate of $2.47. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen’s Q2 2026 earnings at $0.66 EPS, FY2026 earnings at $2.57 EPS, Q4 2027 earnings at $0.74 EPS and FY2027 earnings at $2.85 EPS.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.03. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The firm had revenue of $532.58 million during the quarter, compared to analysts’ expectations of $525.68 million. During the same quarter last year, the company earned $0.60 earnings per share. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year.

A number of other research analysts have also recently issued reports on QGEN. Wall Street Zen cut Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, January 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. Deutsche Bank Aktiengesellschaft lowered shares of Qiagen from a “buy” rating to a “hold” rating and boosted their price target for the company from $52.00 to $54.00 in a research report on Thursday. Citigroup lowered shares of Qiagen from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $57.89 to $52.63 in a report on Thursday, December 11th. Finally, Barclays reaffirmed an “overweight” rating and set a $57.89 price target (up from $55.79) on shares of Qiagen in a report on Monday, December 15th. Two research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $53.04.

Qiagen Price Performance

Qiagen stock opened at $55.56 on Monday. The business has a 50 day simple moving average of $48.88 and a 200 day simple moving average of $49.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.60 and a quick ratio of 2.30. The company has a market capitalization of $11.73 billion, a PE ratio of 28.68, a price-to-earnings-growth ratio of 2.67 and a beta of 0.66. Qiagen has a one year low of $39.61 and a one year high of $57.81.

Hedge Funds Weigh In On Qiagen

Hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC increased its position in Qiagen by 45.6% in the fourth quarter. Farther Finance Advisors LLC now owns 1,730 shares of the company’s stock worth $78,000 after purchasing an additional 542 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in shares of Qiagen by 1.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 24,205,881 shares of the company’s stock valued at $1,088,538,000 after purchasing an additional 264,921 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Qiagen by 10.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 3,164,805 shares of the company’s stock worth $143,018,000 after buying an additional 290,449 shares during the period. Exchange Traded Concepts LLC raised its stake in shares of Qiagen by 14.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 17,634 shares of the company’s stock worth $793,000 after buying an additional 2,263 shares during the last quarter. Finally, Canvas Wealth Advisors LLC raised its stake in shares of Qiagen by 67.8% during the fourth quarter. Canvas Wealth Advisors LLC now owns 9,030 shares of the company’s stock worth $406,000 after buying an additional 3,648 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

More Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Zacks Research nudged its Q1 2027 EPS estimate up to $0.68 from $0.67, a small positive signal for near‑term earnings expectations that may be helping support the stock.
• Neutral Sentiment: Media pieces note that analysts are “conflicted” on Qiagen, highlighting mixed buy/hold/sell views rather than a consensus directional change; this increases focus and trading but doesn’t force a clear fundamental shift. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Neutral Sentiment: A similar roundup notes mixed analyst views again (adds visibility and trading interest but not a unified directional signal). Analysts Conflicted on These Healthcare Names
• Negative Sentiment: Zacks Research lowered multiple quarterly EPS estimates (including Q3 2027 and Q4 2026) and trimmed near‑term forecasts overall — a signal that analysts see some softening in near‑term profit trends. Consensus full‑year EPS remains around $2.26, but the downward quarterly revisions are a near‑term negative for sentiment.
• Negative Sentiment: Deutsche Bank downgraded Qiagen, a direct negative from a major sell‑side firm that can pressure sentiment and weighing on shares despite the mixed analyst picture. Deutsche Bank downgrades Qiagen NV (QGEN)

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.